Week in Review: Luye Acquires Hanmi's Oncology Drug for $20 Million

Luye Pharma in-licensed China rights to a novel oncology drug candidate from Korea's Hanmi Pharma in a $20 million deal; Bao Hao, a Shanghai company, made an equity investment in US-based 20/20 GeneSystems to underwrite a China trial of 20/20's lung cancer diagnostic; Sinopharm signed a MOU to in-license China rights for a cancer immunotherapy from Provectus Biopharma of the US; Suzhou Amerigen Pharma gained CFDA approval to sell generic mecobalamin tablets, its first marketed product; a Wuxi PharmaTech subsidiary passed FDA inspection for manufacture of a commercialized drug API; and Cook Medical of the US began enrolling patients in a China trial of its drug eluting peripheral stent. More details.... Stock Symbols: (HK: 2186) (KRX: 128940) (NYSE: PVCT) (NYSE: WX) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.